Core Viewpoint - On November 17, a total of 13 target price adjustments were made by brokerages for listed companies, with notable increases in target prices for Kangguan Technology, Kede CNC, and Honglu Steel Structure, showing target price increases of 44.60%, 43.03%, and 37.73% respectively, across the optical optoelectronics, general equipment, and professional engineering industries [1][3]. Group 1: Target Price Increases - Kangguan Technology received a target price of 32.00 yuan with a target price increase of 44.60% [3] - Kede CNC was assigned a target price of 86.95 yuan, reflecting a 43.03% increase [3] - Honglu Steel Structure has a target price of 24.42 yuan, indicating a 37.73% increase [3] - Other companies with significant target price increases include Zhongxin International with a target price of 159.30 yuan (35.42% increase) and Sinopec with a target price of 7.60 yuan (31.49% increase) [3] Group 2: Brokerage Recommendations - A total of 51 listed companies received brokerage recommendations on November 17, with Aotewei and Kede CNC each receiving 2 recommendations [4][5] - Aotewei's closing price was 42.55 yuan, while Kede CNC's closing price was 60.79 yuan [5] Group 3: Rating Adjustments - On November 17, brokerages raised ratings for 2 companies, including Sinopec's rating upgraded from "Hold" to "Buy" by Huatai Securities, and Hongyuan Electronics' rating upgraded from "Hold" to "Buy" by CITIC Securities [4] - One company, Honglu Steel Structure, had its rating downgraded from "Strong Buy" to "Recommended" by Huachuang Securities [4] Group 4: First Coverage - On November 17, brokerages initiated coverage on 7 companies, including Wan Energy Power with an "Accumulate" rating from China Merchants Securities, and Hengyin Technology with an "Accumulate" rating from Zhongyou Securities [7][8] - Other companies receiving first coverage include Jinlei Co. with a "Buy" rating, Zhaoyan Pharmaceutical with an "Accumulate" rating, and Weisheng Information with a "Recommended" rating [8]

Core Insights - On November 17, 2023, brokerage firms provided target prices for listed companies, with notable increases for Kangguan Technology, Kede CNC, and Honglu Steel Structure, showing target price increases of 44.60%, 43.03%, and 37.73% respectively [1][3] Group 1: Target Price Increases - Kangguan Technology received a target price of 32.00 yuan, reflecting a 44.60% increase [3] - Kede CNC's target price is set at 86.95 yuan, indicating a 43.03% increase [3] - Honglu Steel Structure has a target price of 24.42 yuan, with a 37.73% increase [3] Group 2: Brokerage Recommendations - A total of 51 listed companies received brokerage recommendations on November 17, with Aotewei and Kede CNC each receiving 2 recommendations [4][5] - Aotewei's closing price was 42.55 yuan, while Kede CNC's closing price was 60.79 yuan [5] Group 3: Rating Adjustments - Two companies had their ratings upgraded on November 17, including China Petroleum, which was upgraded from "Hold" to "Buy" by Huatai Securities, and Hongyuan Electronics, upgraded from "Hold" to "Buy" by CITIC Securities [4] - One company, Honglu Steel Structure, had its rating downgraded from "Strong Buy" to "Recommended" by Huachuang Securities [4] Group 4: First Coverage - Seven companies received initial coverage on November 17, including Waneng Power with an "Accumulate" rating from China Merchants Securities, and Hengyin Technology with an "Accumulate" rating from Zhongyou Securities [7][8] - Other companies receiving first coverage include Jinlei Co., Ltd. with a "Buy" rating, Zhaoyan Pharmaceutical with an "Accumulate" rating, and Weisheng Information with a "Recommended" rating [7][8]

Core Points - The announcement details the release of part of the pledged shares by shareholder Gu Meifang, who currently holds 10,322,035 shares, representing 1.38% of the total share capital of the company [1] - After the release of the pledge, Gu Meifang has a total of 5,000,000 pledged shares, which accounts for 48.44% of her holdings [1] - The company previously announced a cash dividend of 0.40 yuan per share (before tax) and a capital reserve increase of 0.4 shares per share on July 19, 2023 [1] Summary of Key Information - As of the announcement date, Gu Meifang's pledged shares increased from 1,000,000 to 1,400,000 shares following the capital increase [1] - The notice of the release of pledged shares was received on November 17, 2025, and the company is providing specific details in this announcement [1]

Core Viewpoint - The company announced that shareholder Gu Meifang has released the pledge on 1.4 million shares, reducing the total pledged shares to 5 million, which is 48.44% of her holdings [1] Summary by Relevant Sections - **Shareholder Actions** - Gu Meifang has released the pledge on 1.4 million shares as of November 17, 2025 [1] - After the release, Gu Meifang holds a total of 10.322 million shares, representing 1.38% of the company's total share capital [1] - **Pledged Shares** - Following the release of the pledge, the total number of pledged shares held by Gu Meifang is now 5 million [1] - This represents 48.44% of her total shareholding [1]

Group 1 - The core point of the article is that Zhaoyan New Drug (SH 603127) announced the release of share pledges by Gu Meifang, who holds approximately 10.32 million shares, accounting for 1.38% of the company's total share capital [1] - After the release of the pledge, Gu Meifang has a total of 5 million shares pledged, which represents 48.44% of her holdings [1] - For the year 2024, Zhaoyan New Drug's revenue composition is projected to be 95.0% from preclinical research services, 4.95% from clinical services, and 0.04% from sales of laboratory animals and related products [1] Group 2 - As of the announcement, Zhaoyan New Drug has a market capitalization of 23.8 billion yuan [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 证券代码：603127 证券简称：昭衍新药 公告编号：2025-048 北京昭衍新药研究中心股份有限公司 关于股东部分股份解除质押的公告 2025 年 11 月 18 日 2025 年 11 月 17 日，公司接到股东顾美芳女士将其持有公司部分质押股份解除质押的 通知，现将具体情况公告如下： | 股东名称 | | | 顾美芳 | | --- | --- | --- | --- | | 本次解质股份 | | | 1,400,000 | | 占其所持股份比例 | | | 13.56% | | 占公司总股本比例 | | | 0.19% | | 解质时间 | 2025 年 | 11 月 | 14 日 | | 持股数量 | | | 10,322,035 | | 持股比例 | | | 1.38% | | 剩余被质押股份数量 | | | 5,000,000 | | 剩余被质押股份数量占其所持股份比例 | | | 48.44% | | 剩余被质押股份数量占公司总股本比例 | ...

Core Viewpoint - Zhaoyan New Drug (06127) announced the release of 1.4 million shares from pledge by shareholder Gu Meifang, reducing her pledged shares to 5 million, which is 48.44% of her total holdings [1] Summary by Relevant Sections - **Shareholder Actions** - Gu Meifang has released 1.4 million shares from pledge [1] - After the release, Gu Meifang holds a total of 10.322 million shares, representing 1.38% of the company's total share capital [1] - **Pledged Shares** - The total number of pledged shares held by Gu Meifang is now 5 million [1] - This represents 48.44% of her total shareholding [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 董事長 中 國 北 京，2025年11月17日 於 本 公 告 日 期，董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 士、執 行 董 事 高 大 鵬 先 生、孫雲霞女士、羅樨女士及顧靜良先生，及獨立非執行董事張帆先生、楊福全 先 生、陽 昌 雲 先 生 及 應 放 天 先 生。 证券代码：603127 证券简称：昭衍新药 公告编号：2025-048 北京昭衍新药研究中心股份有限公司 海外監管公告 本公告乃北京昭衍新藥研究中心股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條 而 作 出 ...

Market Overview - The medical services sector experienced a decline of 1.69% on November 17, with Meidisi leading the drop [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] Stock Performance - Baihua Pharmaceutical (600721) saw a significant increase of 8.63%, closing at 10.70, with a trading volume of 792,600 shares and a turnover of 846 million [1] - ST Zhongzhu (600568) rose by 4.80%, closing at 2.40, with a trading volume of 404,900 shares [1] - Meidisi (688202) led the decline with a drop of 5.99%, closing at 62.47, with a trading volume of 36,600 shares and a turnover of 232 million [2] - Kanglong Chemical (300759) and Haoyuan Pharmaceutical (688131) also saw declines of 5.34% and 5.21%, respectively [2] Capital Flow - The medical services sector experienced a net outflow of 1.285 billion from institutional investors, while retail investors saw a net inflow of 993 million [2] - Baihua Pharmaceutical had a net inflow of 71.1 million from institutional investors, but a net outflow of 47.2 million from retail investors [3] - Meidisi had a net outflow of 1.29 million from institutional investors, indicating a shift in investor sentiment [3]

南财智讯11月17日电，昭衍新药公告，2025年11月17日，公司接到股东顾美芳女士通知，其于2025年11 月14日将其持有公司的140.00万股股份办理了解除质押手续。本次解除质押后，顾美芳女士累计质押公 司股份数量为500.00万股，占其所持股份的48.44%。 ...